Microbix Schedules Release of Results for Q2 Fiscal 2026

Rhea-AI Summary

Microbix (OTCQX:MBXBF, TSX:MBX) said it will file Q2 fiscal 2026 financial statements, MD&A and a results news release prior to the start of trading on May 14, 2026. A webinar discussion with CEO, CFO and COO is scheduled for 10:00 AM ET that day.

Investors may register via Zoom or watch a live stream and later replay on Adelaide Capital's YouTube channel.

AI-generated analysis. Not financial advice.

News Market Reaction – MBXBF

-4.14%

1 alert

-4.14% News Effect

On the day this news was published, MBXBF declined 4.14%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Results Release and Webinar Discussion on Morning of May 14, 2026

MISSISSAUGA, ON / ACCESS Newswire / May 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF, Microbix^®), a life sciences innovator, manufacturer, and exporter, announces that it expects to file the financial statements, management disclosure and analysis, and results news release for its second quarter of fiscal 2026 ended March 31, 2026 ("Q2 2026") prior to the start of trading on May 14, 2026. At 10:00 AM ET that day, Microbix intends to hold a webinar discussion of Q2 2026 results with its CEO, CFO, and COO.

Investors and shareholders can participate in the webinar, hosted by Adelaide Capital, by registering at: https://us02web.zoom.us/webinar/register/WN_8O4BZDDqQmGB2VZLOHUNfw. It will also be live-streamed to YouTube at: https://www.youtube.com/channel/UC7Jpt_DWjF1qSCzfKlpLMWw.

Phone one-tap:

+12042727920,,86806708870# Canada

+14388097799,,86806708870# Canada

Join via audio:
+1 204 272 7920 Canada

Webinar ID: 868 0670 8870

International numbers available: https://us02web.zoom.us/u/kb0QDB9lcu

A replay of the webinar will also be made available on Adelaide Capital's YouTube channel.

About Microbix Biosystems Inc.

Microbix Biosystems Inc. creates proprietary biological products for human health, with over 120 skilled employees and revenues of C$ 18.6 million in its last reported fiscal year (2025). It enables the worldwide commercialization of diagnostic assays by making a wide range of critical ingredients and devices for the global diagnostics industry, notably antigens for immunoassays and its laboratory quality assessment products (QAPs^™) and reference materials (QUANTDx^™) that support clinical lab proficiency testing, enable assay development and validation, or help ensure the quality of clinical diagnostic workflows. Its antigens drive the antibody tests of approximately 100 diagnostics makers, while QAPs or QUANTDx are sold to clinical lab accreditation organizations, diagnostics companies, and clinical labs. Microbix QAPs are now available in over 30 countries, supported by a network of international distributors. Microbix is ISO 9001 & 13485 accredited, U.S. FDA registered, Australian TGA registered, Health Canada establishment licensed, and provides IVDR-compliant CE marked products.

Microbix also applies its biological expertise and infrastructure to develop other proprietary products and technologies, most notably Kinlytic^® urokinase, a biologic thrombolytic drug used to treat blood clots, and reagents or media to support molecular diagnostic testing (e.g., its DxTM^™ for patient-sample collection). Microbix is traded on the TSX and OTCQX, and headquartered in Mississauga, Ontario, Canada.

Forward-Looking Information

This news release includes "forward-looking information," as such term is defined in applicable securities laws. Forward-looking information includes, without limitation, expected timing of release of financial results, intended discussion of financial results or the outlook for the business, risks associated with its financial results and stability, its current or future products, development projects such as those referenced herein, access to and sales to foreign jurisdictions, engineering and construction, production (including control over costs, quality, quantity and timeliness of delivery), foreign currency and exchange rates, maintaining adequate working capital and raising further capital on acceptable terms or at all, and other similar statements concerning anticipated future events, conditions or results that are not historical facts. These statements reflect management's current estimates, beliefs, intentions, and expectations; they are not guarantees of future performance. The Company cautions that all forward-looking information is inherently uncertain, and that actual performance may be affected by many material factors, some of which are beyond the Company's control. Accordingly, actual future events, conditions and results may differ materially from the estimates, beliefs, intentions, and expectations expressed or implied in the forward-looking information. All statements are made as of the date of this news release and represent the Company's judgement as of the date of this new release, and the Company is under no obligation to update or alter any forward-looking information except as required by applicable law.

Please visit www.microbix.com or www.sedarplus.ca for recent Microbix news and filings.

For further information, please contact Microbix at:

Cameron Groome, CEO (905) 361-8910

Jim Currie, CFO (905) 361-8910

Deborah Honig, Investor Relations Adelaide Capital Markets (647) 203-8793 ir@microbix.com

Copyright © 2026 Microbix Biosystems Inc.

Microbix^®, DxTM^™, Kinlytic^®, QAPs^™, and QUANTDx^™ are trademarks of Microbix Biosystems Inc.

SOURCE: Microbix Biosystems Inc.

View the original press release on ACCESS Newswire

FAQ

When will Microbix (MBXBF) release its Q2 fiscal 2026 results?

Microbix will file Q2 fiscal 2026 results prior to market open on May 14, 2026 with a 10:00 AM ET webinar. According to Microbix, financial statements, MD&A and a results news release will be filed before trading and discussed on the May 14 webinar.

How can investors join the Microbix (MBXBF) Q2 2026 results webinar on May 14, 2026?

Investors can register for the Zoom webinar or view a live YouTube stream at 10:00 AM ET on May 14, 2026. According to Microbix, registration is via the provided Zoom link and the event will be live-streamed and later available as a replay on Adelaide Capital's YouTube channel.

Who will present Microbix (MBXBF) Q2 2026 results during the May 14 webinar?

Microbix's CEO, CFO and COO will participate in the 10:00 AM ET webinar on May 14, 2026. According to Microbix, the three executives will discuss Q2 fiscal 2026 results and answer investor questions during the hosted session.

Will Microbix (MBXBF) make its Q2 2026 financial statements and MD&A public on May 14?

Yes. Microbix expects to file its Q2 2026 financial statements and MD&A prior to the start of trading on May 14, 2026. According to Microbix, those filings will accompany the results news release posted before markets open that morning.

Where will the replay of the Microbix (MBXBF) Q2 webinar be available after May 14?

A replay will be posted on Adelaide Capital's YouTube channel after the live May 14 webinar. According to Microbix, the event will be live-streamed and the replay made available on Adelaide Capital's YouTube channel for later viewing.